1. At a Glance
Sanofi Consumer Healthcare India Ltd (SCHIL) is the Gen-Z kid of the pharma world—incorporated only in 2023 after being spun out of Sanofi India. In just two years, it’s already flexing revenue growth of 28% and profit up 21% in Q2 FY26. The brand sells Combiflam, Allegra, Avil, and DePura—basically the stuff every Indian household has in their kitchen cabinet. The stock only listed in September 2024 and already saw an open offer in May 2025, proving that even private equity couldn’t resist a bottle of OTC painkillers.
2. Introduction
If big pharma were a Bollywood family, Sanofi India would be Amitabh Bachchan—the patriarch with gravitas. Sanofi Consumer Healthcare, spun off in 2023, is Abhishek Bachchan—trying to prove it’s not just “Bachchan lite” but can stand on its own.
The idea behind the demerger was simple: separate the boring prescription drug business from the flashy OTC segment. Consumers don’t remember generic statins, but they remember Combiflam and Allegra. Brand recall in healthcare is priceless—and Sanofi figured that OTC needs its own focused game plan.
So now SCHIL runs as a standalone entity, focusing on “self-care.” Translation: people who Google “quick relief” and grab a pill before seeing a doctor. Pain relief, allergy care, vitamins—it’s not rocket science, but it’s a billion-dollar segment.
But here’s the twist: the company listed only in September 2024. That’s like a toddler entering a marathon. And by May 2025, it already had an open offer from Opal Bidco SAS and Clayton Dubilier & Rice—signaling that global PE giants think Indian OTC is about to pop. Add in the promoter holding jump to 71% in June 2025, and you’ve got drama worthy of a Netflix pharma docuseries.
3. Business Model (WTF Do They Even Do?)
Sanofi Consumer Healthcare is in theOTC pharmabusiness. Think of it as the Kirana shop for healthcare—except with global branding.
- Products:
- Pain relief: Combiflam (the OG college exam savior).
- Allergy: Allegra (for those who sneeze at pollen, dust, or their in-laws) and Avil.
- Vitamins: DePura for wellness warriors.
- Distribution:They’re everywhere—pharmacies, e-pharmacies, hospitals, government tenders, and 29 states of India. Add in e-commerce presence (Flipkart, Amazon), and even millennials buying vitamins with their protein powder are covered.
- Revenue Split (FY24):91% products, 6% services, 1% other ops, 2% interest income. Domestic 91%,
- Exports 9%.
In short: They don’t run hospitals, they don’t cure cancer, but they do make sure you don’t sneeze through office meetings.
4. Financials Overview
Quarterly Results (Q2 FY26 vs Q2 FY25 vs Q1 FY26)
| Metric | Q2 FY26 | Q2 FY25 | Q1 FY26 | YoY % | QoQ % |
|---|---|---|---|---|---|
| Revenue | ₹2,209M | ₹1,726M | ₹1,987M | +28% | +11% |
| PAT | ₹607M | ₹501M | ₹552M | +21% | +10% |
| Exceptional Gain | ₹66M | – | – | – | – |
| EPS (₹ est.) | 6.5 | 5.3 | 5.9 | +23% | +10% |
Commentary:Solid double-digit growth across revenue and profit. The exceptional gain adds seasoning, but even without it, margins are holding strong. Annualised EPS ~₹26 → if listed peers trade at 30–35x, fair multiples are within striking distance.
5. Valuation (Fair Value RANGE Only)
- P/E Method:EPS annualised ₹26 × 25–35 →₹650 – ₹910.
- EV/EBITDA Method:Assuming EBITDA margin 25% on FY26 revenue (~₹8,500M projected), EBITDA ~₹2,125M. Assigning 18–22x EV/EBITDA → FV₹700 – ₹850.
- DCF (ballpark):Growth 15%, discount 12%, terminal 4% → FV ~₹720 – ₹880.
Overall FV Range:₹650 – ₹910This FV range is for educational purposes only and is not investment advice.
6. What’s Cooking – News, Triggers, Drama
- Open Offer (May 2025):CD&R-backed Opal Bidco SAS tried to grab 26% at ₹5.99 Cr. That’s a rounding error in PE land, but signals international appetite.
- KMP Musical Chairs:Surendra Agarwal out, Maithilee Mistry in Jan 2025, and Narahari Naidu parachuted in Aug 2025 as interim CFO. HR must
